Punarnava for Health & Longevity - Quick Reference Sheet

Punarnava for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A root long used in Indian traditional medicine to shed excess fluid and support the kidneys and liver. Its root compounds calm inflammation and protect kidney and liver tissue in animals, consistently. No properly designed human study of the herb on its own has been published. The largest practical uncertainty is what is actually in the bottle. (Full Review)

Protocol

Classical Ayurvedic root preparations
3–6 g root powder daily
Or decoction 50–100 mL twice daily, per the Ayurvedic Pharmacopoeia of India
Standardised extract capsules
250–500 mg once or twice daily
Concentrated root extract; unvalidated against the classical dose
Best time of day
Morning and early afternoon
With or after food; doses after mid-afternoon risk night-time urination and disturbed sleep
Time to effect
Kidney, liver and glucose effects
Not demonstrated
No human study has demonstrated a measurable effect at any timepoint
Increased urine output
Hours to days
If it occurs
Response assessment
4–12 weeks
The point at which Ayurvedic protocols assess response

Benefits

Contraindications
  • Solid-organ transplant recipients on calcineurin inhibitors (tacrolimus, ciclosporin), at any time post-transplant
  • Pregnancy beyond the first trimester, and lactation
  • Chronic kidney disease stage 4 or 5 (filtration rate below 30 mL/min/1.73 m²) outside supervised care
  • Decompensated cirrhosis (Child-Pugh Class B or C), or unexplained liver enzymes above three times the upper limit of normal
  • Anyone taking lithium, clozapine, or theophylline
  • Hereditary haemochromatosis or ferritin above 300 ng/mL, for mandura-containing formulations
  • Symptomatic low blood pressure (seated systolic below 100 mmHg) or recurrent fainting on standing
  • Bhasma and mandura-containing Ayurvedic formulas without certified metal testing
Key Interactions
  • Loop and thiazide diuretics (furosemide, torsemide, hydrochlorothiazide, indapamide)
  • CYP3A4 substrates with a narrow safety margin (apixaban, amiodarone, simvastatin)
  • CYP2D6 substrates (metoprolol, flecainide, tamoxifen, codeine, tricyclics)
  • CYP1A2 substrates (olanzapine, tizanidine)
  • Glucose-lowering drugs (metformin, sulfonylureas, insulin, SGLT2 inhibitors)
  • Antihypertensives (ramipril, lisinopril, losartan, amlodipine)
  • Over-the-counter NSAIDs (ibuprofen, naproxen, diclofenac)
  • Over-the-counter antacids and iron, with mandura-type formulations
  • Supplements with additive diuretic action (dandelion leaf, juniper, horsetail, uva ursi, caffeine, gokshura)
  • Supplements with additive glucose-lowering action (berberine, cinnamon, gymnema, alpha-lipoic acid, chromium)
  • Other CYP-inhibiting botanicals (grapefruit juice, goldenseal, black pepper piperine)

Risk & Side Effects

  • High: Heavy metal contamination of Ayurvedic products
  • Medium: Inhibition of drug-clearing liver enzymes; unpredictable potency from adulteration and batch variability
  • Low: Drug-induced liver injury from mandura formulations; cutaneous allergic reactions; suppression of immune cell activity; fluid and electrolyte depletion with sustained diuresis
  • Speculative: Mitochondrial toxicity from rotenoid chemistry; gastrointestinal intolerance at high doses; interference with oestrogen-dependent signalling; adverse effects in pregnancy

Monitoring

Marker Target Why
eGFR ≥ 90 mL/min/1.73 m² Core outcome the herb is taken for
Serum creatinine 0.6–1.0 mg/dL (women), 0.8–1.2 (men) Detects both benefit and injury
BUN 10–16 mg/dL Sensitive to volume depletion from diuresis
Serum sodium 137–142 mmol/L Primary safety marker for excess diuresis
Serum potassium 4.0–4.5 mmol/L Distinguishes punarnava from loop diuretics
uACR < 10 mg/g Earliest signal of filtration-barrier change
ALT ≤ 20 U/L (women), ≤ 25 (men) Detects the documented liver-injury signal
AST ≤ 25 U/L Pairs with ALT to localise injury
HbA1c 4.8–5.4% Tracks the animal-derived glucose claim
Fasting glucose 75–90 mg/dL Catches additive hypoglycaemia with drugs
Blood pressure (seated and standing) 110–125 / 70–80 mmHg Detects excessive volume loss
Blood lead < 1.0 µg/dL Addresses the highest-evidence product risk
Serum ferritin 50–150 ng/mL Only for mandura-type iron formulations
Body weight No fall greater than 1.5 kg in a week Moves earlier than sodium on excess diuresis

Cadence: Baseline, then electrolytes and weight at two weeks, the full panel at eight weeks, then every six months, with blood lead annually for continuous users.

Qualitative Assessment

  • Ankle, hand and facial swelling, ideally photographed at a fixed time of day
  • Urine frequency and volume, and whether night-time waking to urinate has increased
  • Dizziness or light-headedness on standing, which precedes measurable volume depletion
  • Energy levels and exercise tolerance, especially in hot weather
  • Appetite, nausea and stool consistency, the earliest signs of gastrointestinal intolerance
  • Any new rash, itching or jaundice, which warrant immediate discontinuation